XJPX
4559
Market cap538mUSD
Oct 09, Last price
1,925.00JPY
1D
-0.21%
1Q
-7.45%
Jan 2017
6.71%
Name
Zeria Pharmaceutical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Zeria Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures, sells, imports, and exports pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural and industrial chemicals, and reagents in Japan and internationally. The company operates through Ethical Pharmaceuticals Business and Consumer Healthcare Business segments. It also provides cosmetics, health foods, alcoholic beverages, soft drinks, food additives, livestock feed, hygienic goods, medical devices, health equipment, hygiene facilities and equipment, beauty appliances, and measuring and analytical equipment. The company also offers products in the gastrointestinal field, including therapeutic agents for functional dyspepsia, ulcerative colitis, Crohn’s disease, and gastritis and ulcers; zinc containing anti-ulcerants; oral bowel cleansing agents; laxatives; therapeutic agents for hypophosphatemia, and iron deficiency anemia; long-acting calcium channel blockers; oral NSAID; anti-leukopenia after radiotherapy products; and non-steroidal anti-inflammatory ophthalmic solutions. In addition, it provides consumer healthcare products, such as nutritional health drugs, remedies for gastrointestinal diseases, western herbal medicines, cold remedies, ophthalmic solutions, anti-inflammatory/analgesics, hemorroidal remedies, dermal remedies, quasi-drugs/cosmetics, nutrient tonics, soft drinks/health foods, and food for specified health uses. Further, the company engages in insurance agency and real estate business. The company was formerly known as Zeria Yakusho Kenkyusho Co., Ltd. and changed its name to Zeria Pharmaceutical Co., Ltd. in May 1970. Zeria Pharmaceutical Co., Ltd. was incorporated in 1955 and is headquartered in Tokyo, Japan.
Key people
Sachiaki Ibe
Chairman of the Board, Chief Executive Officer, Representative Director · since 2014
Mitsuhiro Ibe
President, Chief Operating Officer, Representative Director · since 2014
Hiroki Kato
Managing Executive Officer, Chief Director of Asia Business, Director of Asia Business Planning, Director of Asia Business Development · since 2022
Masakazu Sakurai
Managing Executive Officer, Chief Director of European Business, Director of European Business · since 2025
Kazuhiro Akiba
Executive Officer, Director of Pharmaceutical Sales · since 2022
Kenji Kusano
Executive Officer, Chief Director of Consumer Health Care Sales · since 2022
Yuuki Okazawa
Managing Executive Officer, Chief Director of Administration, Director of Human Resources, Director · since 2024
Yoshihiro Hiraga
Executive Officer, Chief Director of Research & Development · since 2022
Mitsuru Iwai
Executive Officer, Chief Director of Production & Logistics · since 2022
Toshiaki Kawagoe
Executive Officer, Chief Director of Reliability Assurance · since 2022
Kenichi Suzuki
Executive Officer, Senior Director of Corporate Planning, Director of Corporate Strategy Promotion · since 2022
Yasuhisa Tanaka
Executive Officer, Chief Director of Finance and Accounting, Director of Finance, Director of Accounting · since 2024
Takeshi Watanabe
Executive Officer, Manager of Central Research Institute · since 2025
Tetsuo Komori
Independent Director · since 2015
Seiji Morimoto
Independent Director · since 2020
Kikuo Nomoto
Independent Director · since 2017
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||